Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

97.48
Delayed Data
As of Apr 20
 +1.29 / +1.34%
Today’s Change
49.19
Today|||52-Week Range
153.99
-23.27%
Year-to-Date

Today’s Trading

Previous close96.19
Today’s open96.40
Day’s range95.24 - 99.16
Volume1,285,479
Average volume (3 months)994,529
Market cap$13.3B
Data as of 4:00pm ET, 04/20/2018

Growth & Valuation

Earnings growth (last year)-13.15%
Earnings growth (this year)-25.30%
Earnings growth (next 5 years)+163.00%
Revenue growth (last year)+90.66%
P/E ratioNM
Price/Sales127.96
Price/Book7.51

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-0.13-0.28%
SGENSeattle Genetics Inc+0.11+0.22%
TSROTESARO Inc-0.63-1.21%
JAZZJazz Pharmaceuticals...-0.77-0.49%
Data as of 4:00pm ET, 04/20/2018

Financials

Next reporting dateMay 10, 2018
EPS forecast (this quarter)-$1.31
Annual revenue (last year)$89.9M
Annual profit (last year)-$490.9M
Net profit margin-545.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts